PMID- 31237132
OWN - NLM
STAT- MEDLINE
DCOM- 20200619
LR  - 20221207
IS  - 2233-6087 (Electronic)
IS  - 2233-6079 (Print)
IS  - 2233-6079 (Linking)
VI  - 43
IP  - 6
DP  - 2019 Dec
TI  - A Lower Baseline Urinary Glucose Excretion Predicts a Better Response to the 
      Sodium Glucose Cotransporter 2 Inhibitor.
PG  - 898-905
LID - 10.4093/dmj.2018.0257 [doi]
AB  - We aimed to identify the clinical variables associated with a better 
      glucose-lowering response to the sodium glucose cotransporter 2 inhibitor 
      ipragliflozin in people with type 2 diabetes mellitus (T2DM). We especially 
      focused on urinary glucose excretion (UGE). This was a single-arm multicenter 
      prospective study. A total of 92 people with T2DM aged 20 to 70 years with 
      glycosylated hemoglobin (HbA1c) levels >/=7.0% and </=9.5% were enrolled. 
      Ipragliflozin (50 mg) was added to the background therapy for these people for 12 
      weeks. After 3 months treatment with ipragliflozin, the mean HbA1c levels were 
      decreased from 7.6% to 6.9% and 62.0% of the people reached the HbA1c target of 
      less than 7.0% (P<0.001). In addition, body weight, blood pressure, and lipid 
      parameters were improved after ipragliflozin treatment (all P<0.001). The 
      baseline HbA1c (r=0.66, P<0.001) and morning spot urine glucose to creatinine 
      ratio (r=-0.30, P=0.001) were independently associated with the HbA1c reduction. 
      Ipragliflozin treatment for 12 weeks improves glycemic control and other 
      metabolic parameters. A higher HbA1c and lower UGE at baseline predicts a better 
      glucose-lowering efficacy of ipragliflozin.
CI  - Copyright (c) 2019 Korean Diabetes Association.
FAU - Hwang, You Cheol
AU  - Hwang YC
AUID- ORCID: 0000-0003-4033-7874
AD  - Department of Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee 
      University School of Medicine, Seoul, Korea.
FAU - Kim, Jae Hyeon
AU  - Kim JH
AD  - Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of 
      Medicine, Seoul, Korea.
FAU - Lee, Byung Wan
AU  - Lee BW
AUID- ORCID: 0000-0002-9899-4992
AD  - Department of Internal Medicine, Severance Hospital, Yonsei University College of 
      Medicine, Seoul, Korea. bwanlee@yuhs.ac.
FAU - Lee, Woo Je
AU  - Lee WJ
AUID- ORCID: 0000-0002-9605-9693
AD  - Department of Internal Medicine, Asan Medical Center, University of Ulsan College 
      of Medicine, Seoul, Korea. lwjatlas@amc.seoul.kr.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20190614
PL  - Korea (South)
TA  - Diabetes Metab J
JT  - Diabetes & metabolism journal
JID - 101556588
RN  - 0 (Glucosides)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (Thiophenes)
RN  - 3N2N8OOR7X (ipragliflozin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Blood Pressure/drug effects
MH  - Body Weight/drug effects
MH  - Diabetes Mellitus, Type 2/*drug therapy/*urine
MH  - Female
MH  - Follow-Up Studies
MH  - Glucosides/*therapeutic use
MH  - Glycated Hemoglobin/analysis
MH  - Glycosuria/*diagnosis
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Republic of Korea
MH  - Sodium-Glucose Transporter 2 Inhibitors/*therapeutic use
MH  - Thiophenes/*therapeutic use
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC6943269
OTO - NOTNLM
OT  - Diabetes mellitus, type 2
OT  - Glycosuria
OT  - Ipragliflozin
OT  - Sodium-glucose transporter 2
COIS- This study was funded by Astellas Pharma Korea Inc.
EDAT- 2019/06/27 06:00
MHDA- 2020/06/20 06:00
PMCR- 2019/12/01
CRDT- 2019/06/26 06:00
PHST- 2018/12/10 00:00 [received]
PHST- 2019/02/13 00:00 [accepted]
PHST- 2019/06/27 06:00 [pubmed]
PHST- 2020/06/20 06:00 [medline]
PHST- 2019/06/26 06:00 [entrez]
PHST- 2019/12/01 00:00 [pmc-release]
AID - 43.e36 [pii]
AID - 10.4093/dmj.2018.0257 [doi]
PST - ppublish
SO  - Diabetes Metab J. 2019 Dec;43(6):898-905. doi: 10.4093/dmj.2018.0257. Epub 2019 
      Jun 14.